To make an appointment, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment online
As a leader in cancer research, Karmanos is able to offer patients access to innovative treatments and clinical trials that are often times not available anywhere else.
To offer hope and longer life to patients with all types of cancer, Karmanos offers the latest types of therapy through our clinical trials program. Through clinical trials, we are creating new knowledge about how therapies fight cancer and provide national leadership in testing these new therapies.
We understand that cancer is a complex disease that demands complex care. We provide each patient with a dynamic, carefully constructed treatment plan focused on their specific cancer and their unique needs.
We listen to you to design a plan that provides you with respect, compassionate care and is responsive to your emotional and practical concerns.
Notification: We are pleased to share that our information technology platforms are restored, and our clinics are fully functional across Michigan. Click here for more information.
Cancer History Project
Morhaf Al Achkar, M.D., Ph.D., MSCR, FAAFP, associate center director of Education at the Barbara Ann Karmanos Cancer Institute, has been living with stage IV ALK-positive lung cancer for nearly eight years. On The Cancer Letter’s Cancer History Project podcast, he shares his journey of learning about his diagnosis. As a physician, he said he is privileged to have the resources and access to care that he has received. However, he has dedicated his career to identifying and looking for ways to address health disparities, access to cancer screening and early detection among minority groups with his ongoing research. Listen below to Dr. Al Achkar’s message of how he had to change his thinking about living with lung cancer and the impact he hopes to make while leading the Office of Cancer Research, Training and Education at Karmanos.
Listen to the full podcast episode and read more about Dr. Al Achkar's story here.